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Introduction {#s1}
============

In the past several decades there has been increasing interest over the impact of natural dietary chemicals on human health. Indeed, several plant-derived compounds---particularly, phytoestrogens---function as endocrine disrupting chemicals (EDCs) by binding estrogen receptors (ERs) and interfering with sex hormone signaling ([@c43]; [@c57]).

Unlike synthetic EDCs such as pesticides (e.g., DDT) and plasticizers (e.g., bisphenol A), which are frequented associated with adverse reproductive effects ([@c62]), phytoestrogens are widely thought to confer a range of beneficial effects. These include estrogenic effects in bone and female reproductive tissues, where phytoestrogens may alleviate the symptoms of menopause and provide protection against certain types of cancers ([@c52]). In addition to reproductive tissues, there is emerging evidence that exposure to dietary phytoestrogens may positively impact the function of multiple organ systems and have a key influential role on normal metabolic processes ([@c9]; [@c16]). The observed beneficial effects of phytoestrogens include improved insulin sensitivity and cholesterol homeostasis as shown using the INS-1E rat insulinoma cell line ([@c44]), decreased atherosclerosis in postmenopausal women ([@c48]), a decline in tumor reoccurrence in breast cancer survivors ([@c45]), and a reduction in ischemic heart disease with enhanced neurological recovery following stroke as shown in a mouse model ([@c32]). Interestingly, dietary phytoestrogen consumption has been both positively ([@c49]; [@c53]) and negatively ([@c11]; [@c56]) associated with body fat content and obesity in experimental studies and positively correlated with obesity in humans ([@c57]; [@c67]), suggesting that multiple factors are at play.

The physiological actions of steroid hormones and certain other hydrophilic molecules are mediated through a family of nuclear receptors that function as ligand-activated transcription factors in target cells ([@c24]; [@c42]). Phytoestrogens manifest their biological and pathological activities through binding to nuclear receptors, modulating their transcriptional responses, and interfering with the signaling pathways regulated by endogenous receptor ligands ([@c43]). In the nuclear receptor field, the majority of studies on phytoestrogens to date have described the ability of many of these agents to modulate ER function and to alter the biology of ER-positive tumors in the breast and other reproductive tissues ([@c56]). However, it is now clear that the nuclear receptor peroxisome proliferator-activated receptor-gamma ($\text{PPAR}\gamma$) is also a target of phytoestrogen action ([@c36]; [@c41]). Indeed, several abundant dietary phytoestrogens are known to augment or disrupt $\text{PPAR}\gamma$ signaling by binding to the receptor and modulating its transcriptional activity, thereby effectively interfering with downstream $\text{PPAR}\gamma$-mediated biological processes ([@c6]; [@c14]; [@c29]; [@c35]; [@c61]). Specifically, genistein and daidzein (isoflavones), which are enriched in soy and other legumes, and resveratrol, which is found in grapes and berries, have been described as $\text{PPAR}\gamma$ modulators ([@c71]).

In the pharmaceutical sciences, $\text{PPAR}\gamma$ is known as the target of thiazolidinedione antidiabetic drugs and clinical trials have shown that the activated receptor vastly improves insulin sensitivity and blood glucose homeostasis ([@c12]). However, the major established physiological role of $\text{PPAR}\gamma$ is in fat storage, where the receptor functions as the master regulator of adipogenesis ([@c38]; [@c66]). The ability of phytoestrogens to modulate $\text{PPAR}\gamma$ activity in multiple cell and tissue types has been established, and previous studies have shown that isoflavones and numerous other phytoestrogens bind directly to $\text{PPAR}\gamma$ ([@c7]; [@c60]; [@c65]). However, the potential link between phytoestrogens and the adipogenic functions of $\text{PPAR}\gamma$ has not been well studied. This relationship is likely significant given that epidemiological studies demonstrate a strong correlation between dietary phytoestrogen exposure, body fat content, and obesity ([@c17]; [@c23]; [@c31]; [@c51]; [@c67]).

Several phytoestrogen ligands for $\text{PPAR}\gamma$, including genistein and resveratrol, are consumed in significant quantities worldwide ([@c2]; [@c8]; [@c52]; [@c57]). This observation prompted a closer look at the relationship between the ability of a phytoestrogen to activate $\text{PPAR}\gamma$ and the subsequent effects on adipogenesis. The current study tests the hypothesis that the pro- or anti-adipogenic effects of resveratrol---and of the soy isoflavones genistein and daidzein---are correlated with their ability to activate or inhibit $\text{PPAR}\gamma$ in adipocytes. Using mammalian adipocytes as a model, the objectives of this study were to (*a*) evaluate the relative agonist/antagonist activities of phytoestrogens on $\text{PPAR}\gamma$, (*b*) characterize the ability of phytoestrogens to promote adipogenesis by activation of $\text{PPAR}\gamma$, and (*c*) determine effects of these agents on classical $\text{PPAR}\gamma$ gene expression and receptor--cofactor interactions.

Methods {#s2}
=======

Biochemicals {#s2.1}
------------

Quantitative polymerase chain reaction (qPCR) reagents were obtained from BIO-RAD. Rosiglitazone, genistein, and daidzein were purchased from Sigma. The $\text{PPAR}\gamma$-specific antagonist GlaxoWellcome9662 (GW9662) was a gift from GlaxoSmithKline Pharmaceuticals. AdipoRed assay reagent was bought from Lonza, and Hoechst 33342 from Sigma. Adipocyte differentiation kits (Adipogenesis Assay Kit item no. 10006908) were purchased from Cayman Chemical Company. Fugene 6 transfection agent and the Dual-Luciferase® Reporter (DLR™) assay system were purchased from Promega. qPCR oligos were obtained from Invitrogen.

Mammalian Cell Culture {#s2.2}
----------------------

3T3-L1 (murine fibroblast) cells, human adipose-derived mesenchymal stem cells, and HeLa (human cervical carcinoma) cells were obtained from American Type Culture Collection (ATCC). 3T3-L1 cells were maintained in Dulbecco's Modified Eagle's Medium (MEM) supplemented with 10% bovine serum (Invitrogen). Human adipose-derived mesenchymal stem cells were maintained in low-serum media purchased as a mesenchymal stem cell growth kit (ATCC: PCS-500-040^TM^). HeLa cells were maintained in MEM supplemented with 10% fetal bovine serum (FBS), $2\,\text{mM}$ glutamine, $0.1\,\text{mM}$ nonessential amino acids, and $1\,\text{mM}$ sodium pyruvate (Invitrogen). The cells were grown in a humidified 37°C incubator with 5% carbon dioxide.

Concentrations of Ligands {#s2.3}
-------------------------

Ligands were prepared from powder in ethanol in $100\text{-}\mu M$, $1\text{-mM}$, $10\text{-mM}$, and a $100\text{-mM}$ stocks for serial dilutions. Ligands in ethanol were stored at $- 20{^\circ}C$. Serial dilutions of the $100\text{-mM}$ stock were used to generate the dose--response studies shown in [Figure 1A--C](#f1){ref-type="fig"}, which included doses ranging from $10\,\text{nM}\,\text{to}\, 10\;\mu M$. These concentrations are relevant to those found in humans; several studies of formula-fed infants have detected average plasma levels of genistein and daidzein of at least $3\;\mu M\,$ and $1\;\mu M$, respectively ([@c8]; [@c30]). Likewise in adults, isoflavone levels have been reported to exceed $4\;\mu M$ in individuals consuming a soy-rich diet ([@c22]). Furthermore, the $10\,\text{nM}–10\;\mu M$ range spans the concentrations of genistein and daidzein that have been shown to bind and activate $\text{PPAR}\gamma$ ([@c55]; [@c60]; [@c65]).

![$\text{PPAR}\gamma$ transcriptional activity was measured in the presence of $\text{PPAR}\gamma$ agonist rosiglitazone, $\text{PPAR}\gamma$ antagonist GW9662, or phytoestrogen ligands. HeLa cells were transiently transfected with a $\text{PPAR}\gamma$ expression plasmid, PEPCK-Luc reporter vector, and a luciferase normalization control. Following transfection, cells were treated with vehicle (Veh) or concentrations ranging from $100\,\text{pmol}$ to $100\;\mu M$ of the following ligands: Rosiglitazone (Rosi), Genistein (Gen), Daidzein (Daid), or Resveratrol (Resv). After 36 h, cells were harvested and Dual-Luciferase assays were performed. Each value was normalized to the internal luciferase control. Each data point is the average of three independent experiments; individual experiments included four technical replicates used for each treatment. Data points represent means $\pm S\,{Es}$. (A) Agonist mode: Cells were treated with Veh or concentrations ranging from $100\,\text{pmol}$ to $100\;\mu M$ of the following ligands: Rosi, Gen, Daid, or Resv. (B) Antagonist mode: To evaluate antagonism of Rosi-stimulated $\text{PPAR}\gamma$ activity, Resv and $\text{PPAR}\gamma$ antagonist GW9662 were used at $100\,\text{pmol}$ to $10\;\mu M$ in the presence or absence of $100\,\text{nM}$ Rosi. (C) Antagonist mode: To evaluate antagonism of Gen- or Daid-stimulated $\text{PPAR}\gamma$ activity, these ligands were used at $100\,\text{pmol}$ to $10\;\mu M$ in the presence or absence of $1\,\text{nM}$ GW9662. (D) Augmentative effects of co-administration of Rosi ($1\;\mu M$) and Gen or Daid ($10\;\mu M$). \*$p < 0.05$ for comparison between Veh and each treatment. (E) Agonist mode on DR1-Luc reporter. Following transfection with the $\text{PPAR}\gamma$ expression plasmid, DR1-Luc reporter vector, and a luciferase normalization control, cells were treated for 36 h with Veh or $1\;\mu M$ Rosi, Gen, Daid, Resv, or GW9662. \*$p < 0.05$ for comparison between Veh and each treatment.](ehp3444_f1){#f1}

Various concentrations of the stocks (1:1,000 dilutions of the $100\text{-}\mu M$, $1\text{-mM}$, and $10\text{-mM}$ stocks in media) were used ([Figure 3A)](#f3){ref-type="fig"}. In the remaining majority of experiments, 1:1,000 dilutions of the $1\text{-mM}$ stock to a final concentration of $1\;\mu M$ was used. Ethanol was used as a vehicle at a 1:1,000 dilution in culture media at a final concentration of 0.1%. The final ethanol concentration for all ligand treatments was also 0.1%.

Adipocyte Differentiation Assays {#s2.4}
--------------------------------

$\text{PPAR}\gamma 2$ activation in pre-adipocytes is required for the route of differentiation into mature adipocytes ([@c69]). A key aspect of the process is the transformation of cells from spindly fibroblasts into spherical cells containing cytoplasmic fat globules that can imaged microscopically. Fibroblasts can be differentiated *in vitro* in a manner that reenacts most of the features characteristic of adipogenesis *in vivo*. 3T3-L1 cells are a well-characterized mouse embryonic fibroblast (pre-adipocyte) cell line routinely used to study adipocyte differentiation. When induced, differentiation of 3T3-L1 cells into mature adipocytes occurs within 7--9 d.

3T3-L1 cells were differentiated using a standard methylisobutylxanthine, dexamethasone, insulin (MDI) differentiation protocol ([@c77]). The insulin, 3-isobutyl-1-methylxanthine (IBMX), and dexamethasone reagents (at 1,000× stock solutions) were included in the adipocyte kits purchased from Cayman Chemical Company. Briefly, for microscopic imaging studies, $400\;\mu L$ of cells were plated in 8-well chamber slides at a density of $4 \times 10^{5}\,\text{cells}/{mL}$ in MEM supplemented with 10% bovine serum. For quantitative adipogenesis assays, $4 \times 10^{4}$ cells were plated in 96-well plates in $100\;\mu L$ media. The cells were allowed to adhere overnight and either used the next day or allowed to grow an additional day until reaching 90% confluence. On experimental day 1, cells were incubated with MEM supplemented with 10% FBS, $1\;\mu M$ insulin, $250\;\mu M$ IBMX, and $0.1\;\mu M$ dexamethasone in the absence or presence of rosiglitazone, GW9662, and/or phytoestrogen ligands. On days 4 and 6, the cells were administered MEM supplemented with 10% FBS and insulin in the presence or absence of rosiglitazone, GW9662, and/or phytoestrogen ligands. For the imaging studies, on day 8 the cells were fixed and stained with Oil Red O according to the manufacturer's instructions. All of the reagents used in the staining, as described below, were part of the adipocyte differentiation assay kit (Cayman Chemical Company). Briefly, the medium was aspirated and cells were incubated in lipid droplet assay fixative for 15 min. The cells were next incubated with a wash solution for 5 min and then repeated. The wells were allowed to dry completely before adding Oil Red O working solution for 20 min. The cells were then washed twice for 5 min, and coverslips were mounted. Slides were viewed and photographed at 200× magnification using a Zeiss Axio Scope.A1 light microscope. For the quantitative studies, on day 8 the cells were incubated with AdipoRed and Hoechst reagent and assayed according to the manufacturers' protocols. Briefly, the medium was removed and each well was washed with phosphate buffered saline (PBS). The cells were fixed in 2% paraformaldehyde for 30 min, washed with PBS, and incubated with AdipoRed assay reagent; after 10 min, fluorescence was read ($\text{Ex}485\,\text{nm}/\text{Em}535$) using a Spectramax i3X plate reader. The cells were co-incubated for 30 min with the nuclear dye Hoechst 33342 and read at Ex330/Em470 in order to quantitate the DNA content to allow for correction for cell number variances between samples. Lipid accumulation values were calculated between treatments by normalizing lipid intensity values to Hoechst intensity. All assays were performed in quadruplicate replicates, and a minimum of three independent studies were performed in each instance.

RNA Isolation and Quantitative PCR {#s2.5}
----------------------------------

For RNA analysis in pre-adipocytes, cells were plated at 60% confluency in 6-well plates in $2\;{mL}$ growth medium. After 24 h, the medium was replaced with fresh media supplemented with 0.01% ethanol (vehicle), rosiglitazone, genistein, daidzein, or resveratrol, in the presence or absence of the $\text{PPAR}\gamma$-specific antagonist GW9662 ([@c37]). The cells were harvested after 24 h. For RNA analysis in mature adipocytes, the cells were differentiated for 7 d and then treated as described above. See the figure captions for details on the concentrations of agents used in specific experiments.

RNA was isolated from cultured 3T3-L1 cells using the RNeasy® kit (Qiagen). Five hundred nanograms of RNA was reverse transcribed using the BioRad iScript™ cDNA synthesis kit. The ABI PRISM® 7900HT Real-Time PCR System was used to amplify and quantitate levels of cDNAs amplified from target genes. qPCR reactions were performed using $0.1\;\mu L$ of cDNA, $10\;\mu M$ gene-specific primers, and 2× SYBR Green. Data are the $\text{means} \pm \text{standard}\,\text{deviations}$ (SDs) of triplicate determinations. All experiments were repeated a minimum of three times.

Adipocyte gene expression was assessed using genes that fit the following criteria: (*a*) they were detectable in a quantitative manner in the 3T3L1 cell model; (*b*) based on literature, they had been shown to display induction by rosiglitazone, and (*c*) they possessed established roles in lipid metabolism. These criteria permitted focus on $\text{PPAR}\gamma$-dependent adipogenic effects of dietary phytoestrogens. A handful of genes met the selection criteria, including fatty acid-binding protein (*FABP*), *PEPCK* (phosphoenolpyruvate carboxykinase) and *HRASLS3* (Hras-like-suppressor 3) ([@c28]; [@c70]).

The following primers were used: FABP, 5′-AAGGTGAAGAGCATCATAACCCT-3′ (for) and 5′-TCACGCCTTTCATAACACATTCC-3′ (rev); HRASLS5, 5′-CAAGCTGGATGGCACATACCT-3′ (for) and 5′-AGTTCCCCTCAATTAGGCTGT-3′(rev); PEPCK, 5′-AGCATTCAACGCCAGGTTC-3′ (for) and 5′-CGAGTCTGTCAGTTCAATACCAA-3′ (rev); and GAPDH 5′-AGGTCGGTGTGAACGGATTTG-3′ (for) and 5′-GGGGTCGTTGATGGCAACA-3′ (rev).

Small Interfering RNA Treatment and Analysis {#s2.6}
--------------------------------------------

For small interfering RNA (siRNA) targeting of $\text{PPAR}\gamma$ expression in adipocytes, 3T3L1 cells were plated in 6-well plates at a density of $3 \times 10^{5}\,\text{cells}/{mL}$. After 1--2 d, when 90% confluence was achieved, cells were induced to differentiate for 8 d using the MDI differentiation protocol described above. Adipocyte differentiation was confirmed by fixing and staining with Oil Red O. Differentiated cells were trypsinized, washed with PBS, counted and transfected with siRNA duplexes by electroporation using the Nucleofector™ II system (Lonza). The siRNA utilized targeted murine $\text{PPAR}\gamma 2$ ($\text{PPAR}\gamma\text{-si}\text{-}1$ and $\text{PPAR}\gamma\text{-si}\text{-}2$; Dharmacon ON-TARGETplus™ J-040712-05-0010 and J-040712-05-0010); or a control nontargeting siRNA duplex (Control si-RNA; Dharmacon D-001810-01-20). Each sample representing a single well was electroporated with $2\,\text{nmol}$ siRNA $\text{duplex}/10^{6}$ cells in a total volume of $100\;\mu L$ Nucleofection™ solution in disposable electroporation cuvettes. The samples were removed from the cuvettes using $500\;\mu L$ pre-warmed medium MEM with 10% FBS, and replated in 6-well plates in an additional $1.5\;{mL}$ prewarmed media. After 48 h, cells were then treated with ligands for 24 h, total RNA was harvested, and cDNA was prepared and used for quantitative gene expression analysis as described above.

Plasmids {#s2.7}
--------

$\text{pcDNA}3.1\text{nV}5\text{-hPPAR}\gamma 1$, a mammalian expression vector, a gift from Dr. Bruce Spiegelman, contains the full-length human $\text{PPAR}\gamma 1$, as described previously ([@c46]). The *PEPCK* ($- 2,000/ + 73$)-luciferase and DR1-Luc reporter constructs have also been described previously ([@c46]). pM and VP16 expression vectors were obtained from Clontech. $\text{pM}\text{-PGC}\text{-}1\alpha$ and pM-ASC-2 contain the yeast Gal4 transcription factor DNA binding domain fused to the nuclear receptor--interacting region of the coactivators $\text{PGC}\text{-}1\alpha$ and ASC-2, respectively. $\text{VP}16\text{-PPAR}\gamma$ contains full-length human $\text{PPAR}\gamma 1$ fused to the VP16 activation domain, and 5x-GAL4-TATA-Luc contains five tandem binding sites for the yeast Gal4 transcription factor, as described previously ([@c46]). The pRL-CMV renilla luciferase normalization vector (Promega Corp.) has also been described previously ([@c25]).

Transient Transfection Assays {#s2.8}
-----------------------------

The effects of different ligands on $\text{PPAR}\gamma$ transcriptional activity was assessed in cultured cells. HeLa cells (human cervical carcinoma) were selected for these studies because they lack expression of ERs and other nuclear receptors that respond to phytoestrogens. These cells, therefore, provide a relatively clean background for the analysis of $\text{PPAR}\gamma$-specific responses. HeLa cells were plated in 24-well plates, 16 h before transfection at a density of $5 \times 10^{4}\,\text{cells}/{mL}$. DNA was introduced into the cells using Fugene 6. Each well received $500\,\text{ng}$ of reporter (PEPCK-Luc or DR1-Luc), $150\,\text{ng}$ of $\text{PPAR}\gamma$ expression plasmid (pcDNA3.1nV5-hPPARy1), and $10\,\text{ng}$ of the pRL-CMV renilla luciferase normalization vector (Promega Corp.). Before transfection, cells were washed with PBS, and $200\;\mu L$ phenol red--free MEM containing 10% charcoal-stripped fetal calf serum (FCS; HyClone Laboratories, Inc.) was added to each well. The cells were incubated with the DNA/fugene mix for 6 h and then ligands in $200\;\mu L$ phenol red--free MEM were added to the cells and incubated for 36 h. Mammalian two-hybrid assays were performed as follows: HeLa cells were plated in 24-well plates, 16 h before transfection at a density of $5 \times 10^{4}\,\text{cells}/{mL}$. DNA was introduced into the cells using Fugene 6. In standard mammalian two-hybrid assays, $500\,\text{ng}$ of reporter (5x-GAL4- TATA-Luc), $500\,\text{ng}$ of $\text{VP}16\text{-PPAR}\gamma 2$, $500\,\text{ng}$ of pM $\left( {\text{Gal}4\text{DBD}} \right)\text{-PGC}\text{-}1\alpha$ or pM (Gal4DBD)-ASC-2, and $10\,\text{ng}$ of the pRL-CMV renilla luciferase normalization vector were used for each well. Before transfection, the cells were washed with PBS, and $200\;\mu L$ of phenol red--free MEM containing 10% charcoal-stripped FCS was added to each well. The cells were incubated with the DNA/fugene mix for 6 h, and then ligands in $200\;\mu L$ of phenol red--free MEM were added to the cells and incubated for 36 h.

All transcriptional and mammalian two-hybrid experiments were analyzed by luciferase assays, which were performed using the Dual-Luciferase Reporter assay system according to the manufacturer's protocols (Promega Corp.). Each value was normalized to the renilla luciferase control, and each data point generated was the average of triplicate determinations. All experiments were repeated three times.

Statistical Analysis {#s2.9}
--------------------

All experiments in this study were repeated a minimum of three independent times, and results are expressed as $\text{means} \pm \text{SDs}$. For adipogenesis assays, three to six biological replicates were used in each experiment; for transfection assays, three biological replicates were used in each experiment; and for RT-PCR, three biological replicates were used in each experiment. In all experiments, statistical comparisons were made between control and treatments using two-sample *t*-tests. Differences of $p < 0.05$ were considered significant. Statistical analysis of data in experiments involving comparison of multiple groups ([Figures 4](#f4){ref-type="fig"} and [5](#f5){ref-type="fig"}) included two-way analysis of variance with multiple comparisons using Fisher's least significant difference.

Results {#s3}
=======

Effect of Genistein, Daidzein, and Resveratrol on $\text{PPAR}\gamma$ Transcriptional Activity {#s3.1}
----------------------------------------------------------------------------------------------

$\text{PPAR}\gamma$ regulates adipogenesis by altering gene expression, an action that requires the transcriptional activity of the receptor. Thus, the ability of phytoestrogens to activate $\text{PPAR}\gamma$ transcriptional activity was first examined. HeLa cells were transfected with a $\text{PPAR}\gamma$ expression vector and a luciferase reporter containing the promoter from the $\text{PPAR}\gamma$-responsive phosphoenolpyruvate carboxykinase gene (PEPCK-Luc). The cells were treated with the $\text{PPAR}\gamma$ agonist rosiglitazone or isoflavone phytoestrogens (genistein, daidzein), including doses ranging from $10\,\text{nM}\,\text{to}\, 10\;\mu M$. Transcriptional responses to ligands were quantified using a luminescent assay (see the "Methods" section). Not surprisingly, rosiglitazone was a potent agonist (half maximal effective concentration, $\text{EC}_{50} = 62\,\text{nM}$), reaching maximal efficacy at a pharmacological concentration of $1\;\mu M$ ([Figure 1A](#f1){ref-type="fig"}). Genistein and daidzein were less potent in the assay ($\text{EC}_{50} = 156$ and $359\,\text{nM}$, respectively), likely reflecting their lower binding affinities for $\text{PPAR}\gamma$ compared with rosiglitazone, as reported previously ([@c60]; [@c65]). However, both agents displayed significant agonist activity; they were approximately 70% efficacious as compared with rosiglitazone. No significant differences were observed when the $\text{PPAR}\gamma 2$ isoform was used in the assays (data not shown).

In parallel, the effect of resveratrol on $\text{PPAR}\gamma$ transcriptional activity was assessed. Compared with the isoflavones, resveratrol lacked agonist activity, and further, functioned as an inverse agonist in that cells treated with resveratrol exhibited basal receptor activity of 50% of that of cells treated with vehicle ([Figure 1A](#f1){ref-type="fig"}). To examine the antagonist mode, the cells were treated with increasing concentrations of resveratrol or $\text{PPAR}\gamma$-specific antagonist GW9662 ([@c1]), together with a constant, activating concentration of rosiglitazone. GW9662 was a potent and efficacious inhibitor, as expected (half maximal inhibitory concentration, $\text{IC}_{50} = 47\,\text{nM}$), reflecting its high affinity for the receptor ([@c1]). Notably, treatment with resveratrol resulted in rosiglitazone-activated $\text{PPAR}\gamma$ activity that was 60% of that of cells treated with rosiglitazone alone ([Figure 1B](#f1){ref-type="fig"}), demonstrating efficacy as an inhibitor, albeit less potent ($\text{IC}_{50} = 614\,\text{nM}$) than the high-affinity antagonist GW9662. GW9662 was also capable of inhibiting genistein- and daidzein-activated $\text{PPAR}\gamma$ transcriptional activity ([Figure 1C](#f1){ref-type="fig"}). In contrast, as shown in [Figure 1D](#f1){ref-type="fig"}, genistein and daidzein lacked antagonist activity and further demonstrated their agonist nature by moderately augmenting the effects of rosiglitazone when added at concentrations yielding maximal efficacy ([Figure 1A](#f1){ref-type="fig"}) (e.g., $1\;\mu M$ rosiglitazone and $10\;\mu M$ genistein or daidzein). Agonist activity of isoflavone phytoestrogens compared with resveratrol was further observed on an alternative and simple promoter context, DR1-Luc ([Figure 1E](#f1){ref-type="fig"}).

Effect of Genistein, Daidzein, and Resveratrol on Adipogenesis in 3T3L1 Cells {#s3.2}
-----------------------------------------------------------------------------

To test the effects of phytoestrogens on adipogenesis, 3T3-L1 cells were plated in microscope chamber slides and differentiation was induced using an established 8-d protocol as part of an adipocyte differentiation assay kit (Cayman Chemical Company). On days 1, 4, and 6 of the assay, the cells were administered vehicle, $\text{PPAR}\gamma$ ligands rosiglitazone or GW9662, or the phytoestrogens genistein, daidzein, or resveratrol. On day 8, lipid droplets were fixed and stained using Oil Red O according to the manufacturer's instructions. Microscopic imaging results from a typical experiment are shown in [Figure 2](#f2){ref-type="fig"}. As expected, in control wells lacking induction media, the cells remained fibroblastic in appearance. In contrast, induced, vehicle-treated wells contained abundant rounded, differentiated cells as exhibited by lipid staining. Compared with vehicle, the cells incubated with genistein or daidzein appeared to contain more mature adipocytes, similar to that seen with rosiglitazone. In contrast, cells in the resveratrol-treated wells appeared similar to those of the administered vehicle ([Figure 2](#f2){ref-type="fig"}).

![Adipogenesis in the presence of the $\text{PPAR}\gamma$ agonist rosiglitazone or phytoestrogen ligands. Adipocyte differentiation assays: 3T3L1 mouse pre-adipocytes were grown to confluence. Adipocyte differentiation was induced using an 8-d protocol (see the "Methods" section). On days 1, 4, and 6 of the assay, cells were treated with vehicle, rosiglitazone ($1\;\mu M$) or phytoestrogens ($1\;\mu M$). On day 8, adipocyte differentiation and lipid accumulation were assayed by fixing and staining lipid droplets using Oil Red O. An undifferentiated control (no induction) is included for comparison. Microscopic imaging is at 200× magnification.](ehp3444_f2){#f2}

Pro- and Anti-Adipogenic Effects of Phytoestrogens in Mammalian Adipocytes {#s3.3}
--------------------------------------------------------------------------

The next objective was to obtain a quantitative assessment of phytoestrogen exposure on adipogenesis. 3T3-L1 cells were plated in 96-well plates, and adipocyte differentiation was induced as described above. On days 1, 4, and 6 of the assay, the cells were administered vehicle, $\text{PPAR}\gamma$ ligands rosiglitazone or GW9662, or phytoestrogens at concentrations ranging from $10\,\text{nM}\,\text{to}\, 10\;\mu M$, which are physiologically relevant and within the ranges shown to bind and activate $\text{PPAR}\gamma$ ([@c5]; [@c7]; [@c8]; [@c18]; [@c55]). On day 8, adipocyte differentiation was quantified using a fluorescent dye for intracellular lipids. Undifferentiated fibroblasts displayed an undetectable signal in the assay; however, differentiated adipocytes treated with vehicle yielded a robust response, set at 1 for comparison ([Figure 3A](#f3){ref-type="fig"}). Compared with vehicle, cells treated with isoflavone phytoestrogens displayed a concentration-dependent 2.5- to 3-fold higher induction in adipogenesis that was comparable to that of rosiglitazone. In contrast, resveratrol lacked stimulatory effects, and at micromolar concentrations functioned as an inverse agonist, resulting in adipogenesis that measured below basal levels. Treatment of cells with $\text{PPAR}\gamma$ antagonist GW9662, at $10\;\mu M$, also resulted in lower induction of adipogenesis compared with vehicle control. This observation is consistent with the known requirement of at least some basal receptor activity for adipose differentiation ([@c3]; [@c58]), which was less preserved at the $10\text{-}\mu M$ dose. Collectively, the results shown in [Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"} indicate that, similar to rosiglitazone, the agonist activity of isoflavone phytoestrogens on $\text{PPAR}\gamma$ transcription was correlated with the ability to induce adipogenesis. In contrast, resveratrol was inhibitory in both regards, behaving similarly to the antagonist GW9662.

![Pro- and anti-adipogenic effects of phytoestrogens in mammalian adipocytes. (A) 3T3L1 mouse pre-adipocytes were grown to confluence and then induced to differentiate using an 8-d protocol (see the "Methods" section). Cells were co-incubated with vehicle (Veh) or various concentrations ($100\,\text{nM}$, $1\;\mu M$, $10\;\mu M$) of $\text{PPAR}\gamma$ agonist Rosiglitazone (Rosi), Genistein (Gen), Daidzein (Daid), Resveratrol (Resv), or $\text{PPAR}\gamma$ antagonist GW9662 during the entire differentiation period with the media replaced every 2 d. After 8 d, cells were assayed for adipogenesis using a quantitative fluorescent assay (AdipoRed™ Adipogenesis Assay Reagent). Cells were co-stained with nuclear dye Hoechst 33342, and lipid accumulation values were calculated between treatments by normalizing lipid intensity values to Hoechst intensity. Graphical values for each treatment represent comparison with Vehicle (set at 1). Each data point is the average of three independent experiments; individual experiments included four technical replicates used for each treatment. An undifferentiated control (Undiff. Control) sample is included for comparison. Bars represent $\text{means} \pm \text{SEs}$. \*$p < 0.05$ for comparison between Veh and each treatment. (B) Human mesenchymal stem cells were grown to confluence and induced to differentiate for 8 d. Cells were co-treated throughout with Veh or $1\;\mu M$ Rosi, Gen, Daid, Resv, or GW9662. Results were assayed and normalized as described above. \*$p < 0.05$ for comparison between Veh and each treatment.](ehp3444_f3){#f3}

To determine whether the adipogenic effects of phytoestrogens could be recapitulated in cells more relevant to humans, adipogenesis assays were performed in human adipose-derived mesenchymal stem cells (ATCC® PCS500011™). This self-propagating, pluripotent cell line is capable of differentiation into mature human adipocytes. Using these cells at confluence, differentiation assays were performed in the presence of $\text{PPAR}\gamma$ ligands as described above. On days 1, 4, and 6 of the assay, the cells were administered vehicle, rosiglitazone, phytoestrogens, or GW9662. On day 8, adipocyte differentiation was quantified by staining with a fluorescent dye for intracellular lipids and with a second fluorescent agent for cell quantification. As seen in differentiated mouse adipocytes, the human cells displayed a pro-adipogenic response to rosiglitazone and the isoflavone phytoestrogens ([Figure 3B](#f3){ref-type="fig"}).

$\text{PPAR}\gamma$ and Adipogenic Effects of Phytoestrogens {#s3.4}
------------------------------------------------------------

To determine whether positive or inhibitory effects of phytoestrogens on adipogenesis are mediated at least in part through $\text{PPAR}\gamma$, pharmacological modification of $\text{PPAR}\gamma$ activity with co-administration of agonist rosiglitazone or antagonist GW9662 was used to assess phytoestrogen dependence on the intact receptor for observed adipogenic effects. GW9662 was administered at $1\;\mu M$, a concentration at which it functioned as an antagonist of other ligands but did not block adipogenesis altogether ([Figures 1B](#f1){ref-type="fig"} and [3](#f3){ref-type="fig"}). Quantitative adipocyte differentiation assays were performed using rosiglitazone, genistein, and daidzein at $1\;\mu M$ throughout the differentiation protocol, as described above. Treatment of cells with each of the ligands resulted in a 2.5- to 3-fold greater induction of adipogenesis compared with vehicle, and this activity was completely attenuated by co-administration of GW9662, indicating receptor-dependence ([Figure 4A](#f4){ref-type="fig"}). When administered alone, GW9662 and resveratrol treatment resulted in lower basal levels of adipogenesis compared with vehicle controls, an effect that was reversed by rosiglitazone ([Figure 4B](#f4){ref-type="fig"}), suggesting $\text{PPAR}\gamma$ dependence.

![Adipocyte differentiation in the presence of $\text{PPAR}\gamma$ agonist rosiglitazone or phytoestrogens with or without the $\text{PPAR}\gamma$ antagonist GW9662. Adipocyte differentiation assays: 3T3L1 mouse pre-adipocytes were grown to confluence and then induced to differentiate. After 8 d, cells were assayed for adipogenesis using a quantitative fluorescent assay (AdipoRed™ Adipogenesis Assay Reagent). Cells were co-stained with nuclear dye Hoechst 33342, and lipid accumulation values were calculated between treatments by normalizing lipid intensity values to Hoechst intensity. Graphical values for each treatment represent comparison with Vehicle (set at 1). Each data point is the average of three independent experiments; individual experiments included four technical replicates used for each treatment. An undifferentiated control (Undiff. Control) sample is included for comparison. (A) Cells were co-incubated with vehicle (Veh) or $1\;\mu M$ $\text{PPAR}\gamma$ agonist Rosiglitazone (Rosi), Genistein (Gen), or Daidzein (Daid) in the absence or presence of $1\;\mu M$ $\text{PPAR}\gamma$ antagonist GW9662 during the entire differentiation period with the media replaced every 2 d. Bars represent $\text{means} \pm \text{SEs}$. \*$p < 0.05$ for comparison between Veh and each treatment. ^+^$p < 0.05$ for comparison between each treatment alone and each $\text{treatment} + \text{GW}9662$. (B) Cells were co-incubated with vehicle (Veh) $10\;\mu M$ Resveratrol (Resv), or GW9662 in the absence or presence of $500\,\text{nM}$ Rosiglitazone (Rosi) during differentiation, and assayed as described above. Bars represent $\text{means} \pm \text{SEs}$. \*$p < 0.05$ for comparison between each treatment and each $\text{treatment} + \text{Rosi}$.](ehp3444_f4){#f4}

Effect of Phytoestrogens on the Expression of $\text{PPAR}\gamma$ Target Genes in Pre-Adipocytes and Differentiated Adipocytes {#s3.5}
------------------------------------------------------------------------------------------------------------------------------

The effect of phytoestrogens on the expression of $\text{PPAR}\gamma$ target genes during adipocyte differentiation was next examined. FABP expression in 3T3L1 pre-adipocytes and differentiated adipocytes was evaluated by real-time PCR. As expected, treatment with rosiglitazone resulted in significantly higher levels of FABP expression (5-fold) in pre-adipocytes, and even higher levels (26.5-fold) in differentiated cells ([Figure 5A,B](#f5){ref-type="fig"}). Strikingly, isoflavone phytoestrogens mirrored rosiglitazone, with pre- and post-differentiation induction levels of FABP 3 to 4-fold and 28-fold, respectively. These activities were attenuated by $\text{PPAR}\gamma$ antagonist GW9662. In contrast, cells treated with resveratrol had lower FABP expression levels than those treated with vehicle. Furthermore, when co-administered with rosiglitazone, resveratrol behaved as an antagonist, as cells treated with both rosiglitazone and resveratrol had FABP expression that was less than 50% of that observed with the agonist-activated receptor.

![Real-time PCR of PPARγ target genes in 3T3L1 pre-adipocytes and differentiated adipocytes in the presence of $\text{PPAR}\gamma$ agonist rosiglitazone or phytoestrogens with or without the $\text{PPAR}\gamma$ antagonist GW9662. 3T3L1 cells were induced to differentiate for 8 d; differentiation was confirmed by staining with Oil Red O. Pre-adipocytes or differentiated adipocytes were treated for 24 h with vehicle (Veh) or $1\;\mu M$ of ligands: Rosiglitazone (Rosi), Genistein (Gen), Daidzein (Daid), or Resveratrol (Resv) in the presence or absence of $1\;\mu M$ of the $\text{PPAR}\gamma$ antagonist GW9662 or $1\;\mu M$ Rosi where indicated. Total RNA was harvested, and cDNA was prepared and used as a template for gene expression analysis by real-time PCR. (A) FABP expression in pre-adipocytes. (B) FABP, (C) PEPCK, and (D) HRASLS3 expression in mature adipocytes. An undifferentiated control (Undiff. Control) was run in parallel. Each data point is the average of three independent experiments; individual experiments included three technical replicates used for each treatment. Bars represent $\text{means} \pm \text{SEs}$. For A--D: \*$p < 0.05$ for comparison between Veh and each single treatment (Rosi, Gen, Daid, Resv). ^+^$p < 0.05$ for comparison between each treatment alone and each $\text{treatment} + \text{GW}9662$. ^§^$p < 0.05$ for comparison between each $\text{treatment} + \text{GW}9662$ and each $\text{treatment} + \text{Rosi}$.](ehp3444_f5){#f5}

Similar studies were carried out to examine phytoestrogen regulation of PEPCK and HRASLS3. No ligand-dependent differences in the expression of either gene were detected in pre-adipocytes (data not shown). Therefore, the results of this analysis were obtained from differentiated adipocytes. As seen for FABP, cells treated with rosiglitazone, genistein, and daidzein had higher expression levels of PEPCK and HRASLS3, and the effects of these agents were lowered by co-treatment with GW9662 ([Figure 5C,D](#f5){ref-type="fig"}). Likewise, treatment of cells with resveratrol did not result in higher PEPCK and HRASLS3 expression. Furthermore, when cells were co-treated with resveratrol and rosiglitazone, levels of gene expression decreased from that seen with rosiglitazone alone.

Effect of siRNAs Knockdown of $\text{PPAR}\gamma$ on Phytoestrogen Induction of $\text{PPAR}\gamma$ Target Genes in Adipocytes {#s3.6}
------------------------------------------------------------------------------------------------------------------------------

To further confirm the requirement for $\text{PPAR}\gamma$ in phytoestrogen-mediated gene regulation, the expression of FABP in differentiated adipocytes was examined in the presence of siRNAs targeting the predominant murine adipocyte isoform $\text{PPAR}\gamma 2$ as well as the second isoform, $\text{PPAR}\gamma 1$. The cells were treated with either of two siRNA duplexes ($\text{PPAR}\gamma\text{-si}\text{-}1$ and $\text{PPAR}\gamma\text{-si}\text{-}2$). A reduction in $\text{PPAR}\gamma$ mRNA was examined using qPCR analysis. An approximately 65--70% reduction in receptor expression was observed with each of the $\text{PPAR}\gamma$ siRNAs in the absence and presence of ligands, whereas no effect was seen in cells receiving a control, nontargeting siRNA duplex ([Figure 6A](#f6){ref-type="fig"}).

![$\text{PPAR}\gamma$ target gene expression in 3T3L1 cells following siRNA reduction in $\text{PPAR}\gamma$ expression and treatment with $\text{PPAR}\gamma$ agonist rosiglitazone or phytoestrogens. (A) siRNA reduction in $\text{PPAR}\gamma$ expression in adipocytes. 3T3L1 cells were induced to differentiate for 7 d; differentiation was confirmed by staining with Oil Red O. Differentiated cells were treated for 48 h with siRNA duplexes targeting murine $\text{PPAR}\gamma 1$ and $\text{PPAR}\gamma 2$ ($\text{PPAR}\gamma\text{-si}\text{-}1$ and $\text{PPAR}\gamma\text{-si}\text{-}2$) or a control nontargeting siRNA duplex (Control si-RNA). Cells were then treated with ligands for 24 h, total RNA was harvested, and cDNA was prepared and used for gene expression analysis. The expression of (B) FABP, (C) PEPCK, and (D) HRASLS3 in 3T3L1 differentiated adipocytes was evaluated by real-time PCR. 3T3L1 cells were induced to differentiate for 7 d and treated with siRNAs as described above. After 48 h, cells were treated for 24 h with vehicle (Veh) or $1\;\mu M$ Rosiglitazone (Rosi), Genistein (Gen), or Daidzein (Daid), or Resveratrol (Resv). Total RNA was harvested, and cDNA was prepared and used for gene expression analysis. Each data point is the average of at least three independent experiments; individual experiments included three technical replicates used for each treatment. Bars represent $\text{means} \pm \text{SEs}$. For A: \*$p < 0.05$ for comparison between the Veh-treated Control si-RNA sample and the $\text{PPAR}\gamma\text{-si}\text{-}1$ and $\text{PPAR}\gamma\text{-si}\text{-}2$ samples for all treatments. For B--D: \*$p < 0.05$ for comparison between each $\text{treatment} + \text{Control}$ siRNA and each $\text{treatment} + \text{PPAR}\gamma\text{-si}\text{-}1$ or $\text{PPAR}\gamma\text{-si}\text{-}2$.](ehp3444_f6){#f6}

In the analysis of FABP expression, ligand-dependent gene induction was observed in both the control and $\text{PPAR}\gamma$ si-RNA samples ([Figure 6B](#f6){ref-type="fig"}). However, the total levels of FABP in the receptor-targeted samples were reduced significantly to approximately 25% of that of control. Similar reduction in ligand-dependent induction of the $\text{PPAR}\gamma$ regulated genes PEPCK and HRASLS3 was observed when the receptor was silenced ([Figure 6C,D](#f6){ref-type="fig"}).

Interaction of $\text{PPAR}\gamma 2$ with the Transcriptional Coactivators $\text{PGC}\text{-}1\alpha$ and ASC-2 in the Presence of Phytoestrogens {#s3.7}
--------------------------------------------------------------------------------------------------------------------------------------------------

Transcriptional cofactors are required for proper $\text{PPAR}\gamma$ activity ([@c54]); therefore, it is predicted that phytoestrogens may interfere with $\text{PPAR}\gamma$ action in adipocytes by modifying the formation of receptor--cofactor complexes. To test this hypothesis, a mammalian two-hybrid assay was used to assess the ability of phytoestrogens to facilitate an interaction between the transcriptional activation function 2 domain of $\text{PPAR}\gamma$ and the NR-interacting domain nuclear receptor-box (NR-box) of the coactivators $\text{PPAR}\gamma$ coactivator-1 alpha ($\text{PGC}\text{-}1\alpha$) activating signal cointegrator 2 (ASC-2). These coactivators are known to interact with $\text{PPAR}\gamma$ in an agonist-dependent manner, and further, are known to play a role in energy metabolism ([@c39]; [@c40]). The mammalian two-hybrid assay utilized in this study is a validated method used previously to study ligand-mediated cofactor recruitment by PPAR receptors ([@c26]; [@c46]).

HeLa cells were transfected with $\text{PGC}\text{-}1\alpha$ (NR-Box) or pM-ASC-2 (NR-Box), containing the yeast Gal4 transcription factor DNA-binding domain fused to the NR-Box of the respective coactivator, together with a $\text{VP}16\text{-PPAR}\gamma$ plasmid. The latter is a chimera of the strong herpes simplex virus VP16 activation domain fused to the N-terminus of full-length $\text{PPAR}\gamma$. Transcriptional readout, a measurement of protein--protein interactions in the assay, was obtained by cotransfection of a luciferase reporter vector containing five tandem Gal4 binding sites (5x-Gal4Luc). Cells transfected with either one or both of the control vectors (pM, VP16) yielded a relatively low signal that was not altered by ligand, setting a low baseline for the assay ([Figure 7](#f7){ref-type="fig"}). A significant level of $\text{PGC}\text{-}1\alpha$ and ASC-2 interaction with $\text{PPAR}\gamma$ was observed in the absence of ligand ([Figure 7A,B](#f7){ref-type="fig"}). This is not surprising given that, in the absence of an added activating ligand, PPARs may reside in an active conformation ([@c3]; [@c26]; [@c58]; [@c63]; [@c72]; [@c74]). Despite the high basal level of coactivator binding to $\text{PPAR}\gamma$ genistein and daidzein were able to enhance the interaction in a manner comparable to the full agonist rosiglitazone ([Figure 7A,B](#f7){ref-type="fig"}). Like GW9662, resveratrol decreased the receptor-ASC-2 interactions below baseline ([Figure 7B](#f7){ref-type="fig"}), consistent with the inverse agonist activity on PPARγ displayed in transcriptional assays ([Figure 1B](#f1){ref-type="fig"}).

![The interaction of $\text{PPAR}\gamma 2$ with the transcriptional coactivators $\text{PGC}\text{-}1\alpha$ and ASC-2 in the presence of $\text{PPAR}\gamma$ agonist rosiglitazone, phytoestrogens, or the $\text{PPAR}\gamma$ antagonist GW9662. HeLa cells were transiently transfected with $\text{VP}16\text{-PPAR}\gamma 2$ and (A) $\text{Gal}4\text{DBD}\text{-PGC}\text{-}1\alpha$ or (B) Gal4DBD-ASC-2 expression plasmid or empty controls (VP16, Gal4DBD) together with a 5xGAL4 luciferase reporter and a luciferase normalization control. Following transfection, cells were treated with vehicle (Veh) or $1\;\mu M$ of Rosiglitazone (Rosi), Genistein (Gen), Daidzein (Daid), Resveratrol (Resv), or $\text{PPAR}\gamma$ antagonist GW9662. After 36 h, cells were harvested and Dual-Luciferase assays were performed. Each value was normalized to the internal luciferase control. Each data point is the average of four independent experiments; individual experiments included three technical replicates used for each treatment. Bars represent $\text{means} \pm \text{SEs}$. The dotted line on each graph indicates the basal level of coactivator interaction with $\text{PPAR}\gamma 2$ for comparison with ligand-mediated interactions. \*$p < 0.05$ for comparison between Veh and each treatment.](ehp3444_f7){#f7}

Discussion {#s4}
==========

The current statistics associated with obesity reflect both its importance in human health and the ongoing initiatives in understanding the causes and treatment of the disease. An estimated 35--40% of U.S. adults are obese ([@c20]). Unfortunately, obese individuals are at a high risk for the leading causes of preventable death: heart disease, stroke, type 2 diabetes, and certain types of cancer ([@c10]). A better understanding of the biological causes of obesity will be important to continue the progress medical science is making toward prevention and treatment of this disease.

Pro- and Anti-Adipogenic Activities of Phytoestrogens {#s4.1}
-----------------------------------------------------

The current study provides evidence that phytoestrogens have both positive and negative effects on adipogenesis, depending on the chemical. The soy isoflavones genistein and daidzein, at concentrations found in humans ([@c8]; [@c22]; [@c30]), were pro-adipogenic, as exhibited by their ability to increase the population of mature fat cells in culture and expression of adipogenic genes. Interestingly, these observations are consistent with data from the World Health Organization, where a significant positive correlation between soy consumption and obesity was revealed in a study of 167 countries ([@c57]). Genistein was also shown to promote adipogenesis and adipose tissue weight in male mice when they were administered doses comparable to those consumed by humans who eat a balanced diet ([@c53]). Likewise, a recent report also concluded that quantities of genistein found in a balanced diet were sufficient to promote both adipogenesis and expression of lipid metabolism genes ([@c76]).

In the past decade, health protective effects of resveratrol are being widely reported, and resveratrol consumption has soared ([@c27]). This movement was driven by an observation called "The French Paradox," which links wine consumption to cardioprotection in those on a high-fat, high-caloric diet ([@c19]). Our findings support the belief that resveratrol may have health benefits and protect against obesity. Specifically, resveratrol was able to reduce basal levels of adipogenesis as well as to antagonize the effects of the pro-adipogenic agent rosiglitazone. In line with our observations, others have recently shown that resveratrol can inhibit differentiation of cultured adipocytes ([@c78]).

The concept of resveratrol as an anti-obesity agent has also been supported by recent studies in both animals and humans. In mice, resveratrol was found to oppose the effects of a high-fat diet by increasing metabolism and insulin sensitivity ([@c4]). Furthermore, resveratrol was shown to protect against ovariectomy-associated weight gain in a mouse model of menopause ([@c64]). Clinical studies of 11 obese men have also documented the beneficial effects of resveratrol on adipose tissue morphology ([@c33]) and metabolic rate ([@c68]). Resveratrol has not received U.S. Food and Drug Administration approval to date; however, nutritional supplements have been on the market for at least 12 y.

Mechanism by Which Phytoestrogens Mediate Adipogenic Activity {#s4.2}
-------------------------------------------------------------

One of the most important observations made in this study was that the effects of phytoestrogens on adipocyte differentiation are correlated with their ability to activate $\text{PPAR}\gamma$. The isoflavone phytoestrogens examined function as bona fide agonists of $\text{PPAR}\gamma$ via their ability to induce $\text{PPAR}\gamma$ target genes in a receptor-dependent manner as well as promote an activating conformational change in the receptor that facilitates coactivator recruitment. These activities were attenuated by co-administration of a $\text{PPAR}\gamma$-specific antagonist, demonstrating that these effects were indeed mediated through the receptor. With regard to genistein and daidzein, their pro-adipogenic activities appeared to require receptor activation and $\text{PPAR}\gamma$-dependent induction of genes involved in lipid metabolism. Although isoflavones are known $\text{PPAR}\gamma$ agonists, our study demonstrates that the agonist activity of isoflavone phytoestrogens on $\text{PPAR}\gamma$ is important for their observed adipogenic effects.

In contrast, our findings also suggest that resveratrol can be classified as a $\text{PPAR}\gamma$ antagonist, as this agent displayed antagonist activity on receptor-dependent gene expression, and when $\text{PPAR}\gamma$-bound, appeared to lack or even inhibit the ability of the receptor to adopt a transcriptionally active conformation. Equally important, was the observation that the anti-adipogenic effects of resveratrol are reversed by rosiglitazone, suggesting that resveratrol reduces adipogenesis through inhibition of $\text{PPAR}\gamma$. Both basal and agonist-activated receptor functions were attenuated by resveratrol, including $\text{PPAR}\gamma$ transcriptional response, gene expression, and coactivator recruitment. One question that remains is whether resveratrol antagonist activity involves direct action on $\text{PPAR}\gamma$ receptor activity. Classical $\text{PPAR}\gamma$ antagonists suppress basal and ligand-activated receptor activity by recruiting transcriptional corepressors ([@c50]). It is therefore reasonable that the anti-adipogenic actions of resveratrol may involve enhanced corepressor association with $\text{PPAR}\gamma$. However, one study showed that resveratrol can target $\text{PPAR}\gamma$ protein for destruction via the ubiquitin--proteasome system, and the authors postulated that this could be the means by which the ligand manifests antagonist activity ([@c21]). It is clear that resveratrol binds within the ligand-binding pocket of the receptor ([@c7]), but whether the antagonist activity involves receptor--cofactor interactions and/or down-regulation of receptor levels remains to be determined. An additional consideration is the possible interaction of resveratrol-bound $\text{PPAR}\gamma$ with other nuclear receptors. Although the observed effects of resveratrol on adipogenesis appear to involve $\text{PPAR}\gamma$, resveratrol is known to bind and modulate the activity of other nuclear receptors in adipocytes, including ERs and the arylhydrocarbon receptor. Thus, it will be interesting to determine the relative contributions of each receptor to the resveratrol responses as well as potential crosstalk as an additional regulatory mechanism.

Concentration and Sex-Dependent Activities of Phytoestrogens {#s4.3}
------------------------------------------------------------

Previous studies have shown that some of the biological activities of genistein and resveratrol are concentration dependent. Examination of the effects of resveratrol on the vasculature revealed that high doses are atherogenic in rabbits ([@c73]), whereas dietary levels provide protection against atherosclerosis in humans, rodents, and cell models ([@c47]). With regard to adiposity, dietary levels of soy were associated with increased adiposity compared with pharmacological levels ([@c53]; [@c76]).

In addition to concentration differences, sex-dependent effects of phytoestrogens have also been reported. For example, a positive association between genistein consumption and obesity has been repeatedly observed in male rodents ([@c13]; [@c53]; [@c76]), whereas female rats fed a lifelong diet enriched with soy exhibited significantly lower body weight, less visceral fat, and smaller adipocytes ([@c34]). One explanation for the sex-dependent effects is the likelihood that phytoestrogens may be also activating ERs in adipose tissue. Unlike $\text{PPAR}\gamma$, activated ERs are anti-adipogenic ([@c15]). Thus, it is possible that gender differences in circulating estrogen levels may impact the relative effect of phytoestrogens on ERs or $\text{PPAR}\gamma$ in males versus females, and perhaps disrupt the balance between the somewhat differing biological actions of the two receptors' responses.

Conclusions {#s5}
===========

The present studies demonstrate that the pro- or anti-adipogenic effects of phytoestrogens were related to their ability to activate or inhibit $\text{PPAR}\gamma$ signaling in adipocytes. These findings provide a possible mechanistic explanation for epidemiological studies that associate soy consumption with adiposity and resveratrol with lean body mass. Given the current challenges in obesity treatment and prevention, it will be important to further characterize the adipogenic activities of phytochemicals and the potential impact of their consumption toward human health.
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